Diagnostic utility of a second minor salivary gland biopsy in patients with suspected Sjögren's syndrome: A retrospective cohort study.


Journal

Joint bone spine
ISSN: 1778-7254
Titre abrégé: Joint Bone Spine
Pays: France
ID NLM: 100938016

Informations de publication

Date de publication:
01 2023
Historique:
received: 20 04 2022
revised: 29 07 2022
accepted: 07 09 2022
pubmed: 16 9 2022
medline: 19 1 2023
entrez: 15 9 2022
Statut: ppublish

Résumé

To determine whether repeated minor salivary gland biopsy (MSGB) has a clinical diagnostic utility in patients with suspicion of Sjögren's syndrome (SS). Clinical, biological, pathological data and physician's diagnosis after each MSGB from patients with suspected primary or secondary SS who had benefited from 2 MSGB at Brest University Hospital between January 1st, 1990 and January 14th, 2015, were retrospectively collected. We compared the characteristics of patients with and without first positive MSGB, concordance between the MSGB, and analyzed the modifications of diagnosis after the second MSGB. Ninety-three patients were included, first MSGB was positive for 23 and negative for 70. Patients with first positive MSGB had more often renal involvement (P<0.05) and hypergammaglobulinemia (P=0.01), anti-SSA antibodies (P<0.05) and positive second biopsy with focus score ≥ 1 or Chisholm>2 (P<0.01). The mean time between the 2 MSGB was 5.7±4.3 years. The concordance between the results of the 2 biopsies was low (κ = 0.34). MSGB influenced diagnostic's change in 10 cases where the second MSGB was always guided by new specific clinical manifestations. We observed a low concordance between 2 MSGB in patients with suspected pSS in our study. Despite this variability, performing a second MSGB changed the initial diagnosis in only a minority of the patients and was particularly useful when clinical manifestations had deeply evolved.

Identifiants

pubmed: 36108904
pii: S1297-319X(22)00119-1
doi: 10.1016/j.jbspin.2022.105459
pii:
doi:

Substances chimiques

2'-carbomethoxyphenyl 4-guanidinobenzoate 89022-11-7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105459

Informations de copyright

Copyright © 2022 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Guillermo Carvajal Alegria (G)

Rheumatology Department, CHRU de Brest, site Cavale Blanche, Brest, France; Inserm, LabEx IGO, UMR1227, Lymphocytes B et Autoimmunité, Université de Bretagne Occidentale, Brest, France.

Thibaud Depinoy (T)

Rheumatology Department, CHRU de Brest, site Cavale Blanche, Brest, France.

Valérie Devauchelle-Pensec (V)

Rheumatology Department, CHRU de Brest, site Cavale Blanche, Brest, France; Inserm, LabEx IGO, UMR1227, Lymphocytes B et Autoimmunité, Université de Bretagne Occidentale, Brest, France.

Sandrine Jousse-Joulin (S)

Rheumatology Department, CHRU de Brest, site Cavale Blanche, Brest, France; Inserm, LabEx IGO, UMR1227, Lymphocytes B et Autoimmunité, Université de Bretagne Occidentale, Brest, France.

Thierry Marhadour (T)

Rheumatology Department, CHRU de Brest, site Cavale Blanche, Brest, France.

Dewi Guellec (D)

Rheumatology Department, CHRU de Brest, site Cavale Blanche, Brest, France; CIC Inserm 1412, CHRU de Brest, Brest, France.

Pascale Marcorelles (P)

Pathology Department, CHRU de Brest, site Morvan, Brest, France.

Jacques-Olivier Pers (JO)

Inserm, LabEx IGO, UMR1227, Lymphocytes B et Autoimmunité, Université de Bretagne Occidentale, Brest, France.

Alain Saraux (A)

Rheumatology Department, CHRU de Brest, site Cavale Blanche, Brest, France; Inserm, LabEx IGO, UMR1227, Lymphocytes B et Autoimmunité, Université de Bretagne Occidentale, Brest, France.

Divi Cornec (D)

Rheumatology Department, CHRU de Brest, site Cavale Blanche, Brest, France; Inserm, LabEx IGO, UMR1227, Lymphocytes B et Autoimmunité, Université de Bretagne Occidentale, Brest, France. Electronic address: divi.cornec@chu-brest.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH